SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- cardiovascular

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tnsaf2/14/2008 12:30:27 AM
   of 214
 
Remodeling of ryanodine receptor complex causes "leaky" channels: A molecular mechanism for decreased exercise capacity

Published online on February 11, 2008, 10.1073/pnas.0711074105 OPEN ACCESS ARTICLE
pnas.org
Could also have possibilities as performance enhancing drugs<g>

Andrew M. Bellinger*,{dagger}, Steven Reiken*,{dagger}, Miroslav Dura*,{dagger}, Peter W. Murphy*,{dagger}, Shi-Xian Deng{ddagger}, Donald W. Landry{ddagger}, David Nieman§, Stephan E. Lehnart*,{dagger}, Mahendranauth Samaru*,{dagger}, Alain LaCampagne¶, and Andrew R. Marks*,{dagger},{ddagger},||

*Clyde and Helen Wu Center for Molecular Cardiology, Departments of {dagger}Physiology and Cellular Biophysics and {ddagger}Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032; §Department of Health, Leisure, and Exercise Science, Appalachian State University, Boone, NC 28608; and ¶Institut National de la Santé et de la Recherche Médicale, U 637, Unité de Formation et de Recherche de Médecine, Université Montpellier 1, F-34925 Montpellier, France

Contributed by Andrew R. Marks, November 21, 2007 (sent for review October 31, 2007)

Abstract

During exercise, defects in calcium (Ca2+) release have been proposed to impair muscle function. Here, we show that during exercise in mice and humans, the major Ca2+ release channel required for excitation–contraction coupling (ECC) in skeletal muscle, the ryanodine receptor (RyR1), is progressively PKA-hyperphosphorylated, S-nitrosylated, and depleted of the phosphodiesterase PDE4D3 and the RyR1 stabilizing subunit calstabin1 (FKBP12), resulting in "leaky" channels that cause decreased exercise tolerance in mice. Mice with skeletal muscle-specific calstabin1 deletion or PDE4D deficiency exhibited significantly impaired exercise capacity. A small molecule (S107) that prevents depletion of calstabin1 from the RyR1 complex improved force generation and exercise capacity, reduced Ca2+-dependent neutral protease calpain activity and plasma creatine kinase levels. Taken together, these data suggest a possible mechanism by which Ca2+ leak via calstabin1-depleted RyR1 channels leads to defective Ca2+ signaling, muscle damage, and impaired exercise capacity.

muscle fatigue | calcium channel | calstabin | exitation–contraction coupling | rycals

Footnotes

Author contributions: A.M.B., S.R., M.D., S.-X.D., D.W.L., D.N., S.E.L., A.L., and A.R.M. designed research; A.M.B., S.R., M.D., P.W.M., S.-X.D., D.N., S.E.L., M.S., and A.L. performed research; S.-X.D., D.L., and D.N. contributed new reagents/analytic tools; A.M.B., S.R., M.D., P.W.M., S.-X.D., D.W.L., D.N., S.E.L., M.S., A.L., and A.R.M. analyzed data; and A.M.B. and A.R.M. wrote the paper.

Conflict of interest statement: A.R.M. and D.W.L. are on the scientific advisory board and own shares in ARMGO Pharma, Inc., a start-up company that is developing RyR targeted drugs for clinical use in the treatment of heart failure and sudden death. S.R. is a consultant for ARMGO Pharma, Inc.

||To whom correspondence should be addressed. E-mail: arm42@columbia.edu
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext